A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines
Open accessAbstract
Unlike mRNA vaccines based only on the spike protein, inactivated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines should induce a diversified T cell response recognizing distinct structural proteins. Here, we perform a comparative analysis of SARS-CoV-2-specific T cells in healthy individuals following vaccination with inactivated SARS-CoV-2 or mRNA vaccines. Relative to spike mRNA vaccination, inactivated vaccines elicit a lower magnitude of spike-specific T cells, but the combination of membrane, nucleoprotein, and spike-specific T cell response is quantitatively comparable with the sole spike T cell response induced by mRNA vaccine, and they efficiently tolerate the mutations characterizing the Omicron lineage. However, this multi-protein-specific T cell response is not mediated by a coordinated CD4 and CD8 T cell expansion but by selective priming of CD4 T cells. These findings can help in understanding the role of CD4 and CD8 T cells in the efficacy of the different vaccines to control severe COVID-19 after Omicron infection.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Based on previous reports, the Omicron variant has a strong ability to evade B-cell-mediated humoral immunity, while T-cell epitopes are relatively unchanged.
“Based on previous reports, the Omicron variant has a strong ability to evade B-cell-mediated humoral immunity, while T-cell epitopes are relatively unchanged [24].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 78 · Cited by 73
Research works printed but not linked: 1
- [6]Jeewandara C. Aberathna I.S. Pushpakumara P.D. Kamaladasa A. Guruge D. Wijesinghe A. Gunasekera B. Ramu S.T. Kuruppu H. Ranasinghe T. Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine Immun. Inflamm. Dis. 10 2021 10.1101/2021.10.14.21265030 2021.10.14.21265030 PMC9091995 35634958 · DOI
- Authors
- Lim, J. M. E., Hang, S. K., Hariharaputran, S., Chia, A., Tan, N., Lee, E. S., Chng, E., Lim, P. L., Young, B. E., Lye, D. C., Le Bert, N., Bertoletti, A., & Tan, A. T.
- Affiliations
- Duke-NUS Medical School (SG)
- NHG Polyclinics (SG)
- Tan Tock Seng Hospital (SG)
- National University of Singapore (SG)
- Corresponding author
- Bertoletti, Antonio
- Tan, Anthony T.
- ORCID
- Venue
- Cell Reports Medicine
- Publisher
- Elsevier BV
- Published
- 2022-11
- Volume
- 3
- Issue
- 11
- Pages
- 100793
- ISSN
- 2666-3791 (ISSN-L)
- PMC
- PMC9534788
- OpenAlex
- W4302287373
- Cited by
- 73
- References
- 78
- Citations by year
- 2026: 7 · 2025: 18 · 2024: 19 · 2023: 27 · 2022: 2
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cell Reports Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Ministry of Health -Singapore
- National Medical Research Council (COVID19RF-008, COVID19RF-001, COVID19RF3-0060)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- SARS-CoV-2, COVID-19 vaccines, inactivated vaccine, mRNA vaccines, T cell response, spike protein, membrane proteins, nucleocapsid protein, CD4+ T cells, CD8+ T cells, T cell priming, vaccine comparison
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, Humans, RNA, Messenger, Viral Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
